瑞博生物正式登陆港交所：市值超120亿港元，磐霖资本十年六轮支持耐心陪伴

Core Viewpoint - Suzhou Ribo BioTechnology Co., Ltd. (Ribo Bio) officially listed on the Hong Kong Stock Exchange on January 9, 2026, with a market capitalization exceeding HKD 12 billion, marking a significant milestone in China's small nucleic acid drug industry [3][5]. Company Overview - Founded in 2007, Ribo Bio is a global leader in the research and development of small interfering RNA (siRNA) drugs and one of the earliest pioneers in this field in China [3][4]. - The company has established a comprehensive small nucleic acid drug technology platform that supports all stages of drug development, from early research to commercialization [4]. Technology and Product Pipeline - Ribo Bio has developed the RiboGalSTARTM platform based on proprietary intellectual property and clinically validated GalNAc delivery technology, with a rich product pipeline in cardiovascular, metabolic, liver, kidney diseases, and other therapeutic areas, advancing multiple products into clinical phases II and III [4][6]. Investment Journey - Ribo Bio has received investments from numerous well-known institutions, with Panlin Capital being a significant early investor since 2015, providing crucial funding during challenging times for the company [4][6]. - Panlin Capital's investment strategy focuses on identifying innovative drug development companies addressing unmet clinical needs, aligning with Ribo Bio's mission [6][7]. Milestones and Achievements - The successful IPO of Ribo Bio represents a key achievement for Panlin Capital, following their previous success with another biotech company, highlighting their commitment to supporting the long-term development of China's innovative drug industry [5][8]. - Ribo Bio's journey from a scientific laboratory to the global capital market illustrates the potential of small nucleic acid technology as a new wave in modern pharmaceuticals, capable of targeting intracellular proteins and addressing significant clinical needs [6][7].